Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial
Artículo de investigación publicado en BMC Veterinary Research
10 de marzo de 2016
BACKGROUND:
Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress.
RESULTS:
Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group.
CONCLUSIONS:
The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI
Segarra S., Martinez-Subiela S., Cerda-Cuellar M., Martinez-Puig D., Munoz-Prieto A., Rodriguez-Franco F., Rodriguez-Bertos A., Allenspach K., Velasco-Franco A. y Ceron J.
| R&D Bioiberica. | |
 | Campus de Excelencia Mare Nostrum. Universidad de Murcia (UM). |
| Departamento de Medicina y Cirugía Animal. Facultad de Veterinaria. Universidad de Murcia (UM). |
 | Centre de Recerca en Sanitat Animal (CReSA). Universitat Autònoma de Barcelona (UAB). |
 | Instituto de Investigación y Tecnología Agroalimentarias (IRTA). Generalitat de Catalunya. |
 | Departamento de Medicina y Cirugía Animal. Facultad de Veterinaria. Universidad Complutense (UCM). |
| Servicio de Patología y Veterinaria Forense (SAP). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM). |
 | Department of Veterinary Clinical Sciences and Services. Royal Veterinary College. University of London. |
